InsidersTradesSigma
Track the Chinook Therapeutics, INC. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Chinook Therapeutics, INC. has published 85 insider filings. The latest transaction was disclosed on 11 August 2023 (Disposition). Among the most active insiders: Jerel Davis. Every trade is accessible without an account.
85
Insider Decl.
n/a
Thresholds
€25m
8 ops.
Buy Volume
€40m
19 ops.
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 August 2023
Declarations85 total
3,300 sharesCommon StockSEC:0001209191-23-045422:0
150,777 sharesCommon StockSEC:0001209191-23-045418:0
1,275 sharesCommon StockSEC:0001209191-23-045428:0
447,013 sharesCommon StockSEC:0001209191-23-045415:0
301,138 sharesCommon StockSEC:0001209191-23-045417:0
13,300 sharesCommon StockSEC:0001209191-23-045430:0
19,157 sharesCommon StockSEC:0001209191-23-045424:0
39,371 sharesCommon StockSEC:0001209191-23-045414:0
3,300 sharesCommon StockSEC:0001209191-23-045411:0
23,643 sharesCommon StockSEC:0001209191-23-045420:0
3,333 sharesCommon StockSEC:0001209191-23-044071:0
3,300 sharesCommon StockSEC:0001209191-23-033187:0
3,300 sharesCommon StockSEC:0001209191-23-033190:0
3,300 sharesCommon StockSEC:0001209191-23-033189:0
3,300 sharesCommon StockSEC:0001209191-23-033191:0
3,300 sharesCommon StockSEC:0001209191-23-033188:0
3,300 sharesCommon StockSEC:0001209191-23-033186:0
25,000 shares@ US$0.422.9% of flowCommon StockSEC:0001209191-23-025720:0
295,808 shares@ US$20.750714.1% of flowCommon StockSEC:0000899243-23-011458:0
2,500 shares@ US$0.352.0% of flowCommon StockSEC:0001209191-23-023351:0
2,199 sharesCommon StockSEC:0001209191-23-023108:0
240,000 shares@ US$22.7513.0% of flowCommon StockSEC:0000899243-23-006968:0
2,435 sharesCommon StockSEC:0001209191-23-009776:0
20,248 sharesCommon StockSEC:0001209191-23-009773:0
6,803 sharesCommon StockSEC:0001209191-23-009766:0
25 of 85 declarations
关于 Chinook Therapeutics, INC.
CHINOOK THERAPEUTICS, INC.（股票代码KDNY）是一家美国生物制药公司，专注于肾脏疾病，历史上在美国市场纳斯达克上市（NYSE/NASDAQ背景）。Chinook总部位于美国华盛顿州西雅图，由一支拥有深厚生物技术和风险投资经验的团队于2019年创立，其核心理念明确：为治疗选择有限且医疗需求未得到满足的罕见、严重慢性肾脏疾病开发精准药物。其业务概况是一家临床阶段公司，而非商业制药集团，企业价值主要由管线进展、临床数据公布和监管里程碑驱动。([cbinsights.com](https://www.cbinsights.com/company/chinook-therapeutics?utm_source=openai)) 公司的核心使命是发现、开发和商业化用于肾脏病适应症的疗法，例如IgA肾病（IgAN）、局灶性节段性肾小球硬化症（FSGS）、Alport综合征、原发性高草酸尿症和其他罕见慢性肾脏疾病。Chinook的平台结合了单细胞RNA测序、人源类器官和转化模型，以识别肾脏疾病生物学中差异化的作用机制。关键的临床和临床前项目包括atrasentan、BION-1301和CHK-336，反映了以专业化、高未满足需求适应症为中心的管线策略，而非广泛的初级保健市场。([globenewswire.com](https://www.globenewswire.com/news-release/2021/11/30/2342968/35377/en/chinook-therapeutics-announces-formation-of-sanreno-therapeutics-a-joint-venture-to-develop-kidney-disease-therapies-in-china.html?utm_source=openai)) 在竞争方面，Chinook旨在精准肾脏病学领域脱颖而出，这是一个相对集中的领域，科学差异化和强大的临床证据至关重要。其地理足迹主要在美国，以西雅图为运营中心，但它也通过SanReno寻求国际扩张，SanReno是一家合资企业，旨在选定的亚洲市场开发、制造和商业化肾脏疾病疗法。这种结构表明其有雄心在除美国国内市场之外建立更广泛的区域影响力。([globenewswire.com](https://www.globenewswire.com/news-release/2021/11/30/2342968/35377/en/chinook-therapeutics-announces-formation-of-sanreno-therapeutics-a-joint-venture-to-develop-kidney-disease-therapies-in-china.html?utm_source=openai)) 最近最重要的进展是Chinook于2023年被诺华收购。SEC文件和交易所通知显示，股东批准了合并，并且公司的KDNY证券作为交易的一部分进行了转换，此后Chinook不再作为独立的上市公司运作。因此，对于投资者而言，Chinook应被视为一项被收购的生物技术资产，其管线价值最终通过战略性收购而非作为一家持续独立的上市公司得到认可。([sec.gov](https://www.sec.gov/Archives/edgar/data/1435049/000119312523164896/d511815ddefa14a.htm?utm_source=openai))
